RACHEL ROYLANCE: Open Payments
NPI 1770095432 · LONGVIEW, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,574 in 113 payments from 36 companies in 2025. Trend: 2023 $2,025 · 2024 $2,475 · 2025 $2,574
Food & beverage: $2,460Education: $114
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 13 | $281 |
| AstraZeneca Pharmaceuticals LP | 13 | $276 |
| ABBVIE INC. | 14 | $263 |
| Astellas Pharma US Inc | 5 | $160 |
| Alkermes, Inc. | 2 | $152 |
| Lilly USA, LLC | 7 | $147 |
| Viatris Specialty LLC | 6 | $139 |
| GlaxoSmithKline, LLC. | 7 | $115 |
| Novartis Pharmaceuticals Corporation | 4 | $112 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $98 |
Products named: AIRSUPRA, EVENITY, VRAYLAR, YUPELRI, LYBALVI, TRELEGY ELLIPTA, OTEZLA, LEQVIO.
Industry payments across WA — which companies pay providers there.
